Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Lineage Commitment

Lineage Commitment

Commitment is the process whereby stem cells:

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies.

Blood cancer discovery·2026

Same author

Generation and single-cell characterization of functional megakaryocytes derived from umbilical cord blood.

Stem cell research & therapy·2026

Same author

Prognostic impact of clinico-genetic characteristics and donor types in <i>NPM1</i>-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.

Cell transplantation·2026

Same author

Small-molecule inhibition of YTHDC1 as a strategy against acute myeloid leukemia in mouse models.

Science translational medicine·2026

Same author

Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD<sup>+</sup> to eradicate KRAS-driven AML.

Cell metabolism·2026

Same author

The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells.

bioRxiv : the preprint server for biology·2026

Search research articles

Related Experiment Video

Updated: May 16, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

How close are we to targeting the leukemia stem cell?

Shanshan Pei¹, Craig T Jordan

¹University of Rochester School of Medicine, Wilmot Cancer Center, 601 Elmwood Avenue, Rochester, NY 14642, USA. Shanshan_Pei@URMC.Rochester.edu

Best Practice & Research. Clinical Haematology

|December 4, 2012

Summary

Targeting leukemic stem cells (LSCs) involves exploiting their unique properties and metabolism. Agents like parthenolide selectively kill LSCs by disrupting glutathione pathways, sparing normal stem cells.

More Related Videos

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

Related Experiment Videos

Last Updated: May 16, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

Area of Science:

Oncology
Stem Cell Biology
Molecular Medicine

Background:

Leukemic stem cells (LSCs) are crucial for leukemia development and resistance.
Targeting LSCs is a promising strategy for durable remission.
Current approaches include targeting self-renewal, quiescence, immune mechanisms, and tumor physiology.

Purpose of the Study:

To explore novel strategies for selective LSC targeting.
To investigate the role of oxidative stress and glutathione metabolism in LSC survival.
To evaluate the efficacy of agents like parthenolide against LSCs.

Main Methods:

Review of existing LSC targeting strategies.
Analysis of the mechanism of action of small molecules like parthenolide.
Focus on the aberrant glutathione metabolism pathway in LSCs.

Main Results:

Parthenolide inhibits LSC response to oxidative stress.
LSCs and bulk leukemia cells become susceptible to cell death.
Normal stem cells are relatively unharmed by parthenolide.
The mechanism involves aberrant glutathione metabolism in leukemic cells.

Conclusions:

Targeting LSC-specific vulnerabilities, such as glutathione metabolism, offers a selective therapeutic window.
Parthenolide demonstrates potential as an LSC-targeting agent by exploiting these vulnerabilities.
This approach may lead to more effective and less toxic leukemia treatments.